Cholangiocarcinoma News

Quality-of-Life Trends Associated with Ivosidenib in Patients with CCA and IDH1 Mutation in the ClarIDHy Study

March 2022, Vol 3, No 1

Ivosidenib is a first-in-class inhibitor of IDH1 mutation that is indicated for the treatment of previously treated, locally advanced or metastatic cholangiocarcinoma (CCA) and IDH1 mutation. This indication was approved based on the results of the phase 3 ClarIDHy clinical trial, which demonstrated significant improvement in progression-free survival with ivosidenib compared with placebo in patients with previously treated, unresectable or metastatic CCA harboring IDH1 mutations.1,2

At the 2022 ASCO GI Cancers Symposium, Christina X. Chamberlain, PhD, of Servier Pharmaceuticals, Boston, MA, presented the results of a longitudinal assessment of health-related quality of life (QOL) in ivosidenib-treated patients enrolled in the ClarIDHy study.

The eligibility criteria in the ClarIDHy study included unresectable or metastatic CCA, centrally confirmed IHD1 mutations by next-generation sequencing, measurable disease, and use of 2 previous therapies. Eligible patients were randomized (2:1) to ivosidenib (500 mg once daily in continuous 28-day cycles) or to placebo. The study design allowed crossover from the placebo to the ivosidenib arm at radiographic progressive disease. Health-related QOL was a secondary end point of the study.

The QOL was assessed before dosing on cycle 1, day 1, every 4 weeks on the first day of subsequent cycles, and every 12 weeks thereafter, until the start of a new anticancer therapy. QOL assessments were done using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and the Cholangiocarcinoma and Gallbladder Cancer module (QLQ-BIL21) instruments; the prespecified domains of interest were physical functioning, pain, and appetite loss. A 12 to 13 point score decrease was estimated to be the threshold for clinically meaningful decline in the EORTC QLQ-C30 physical functioning subscale, and 10-point decline was the threshold for other assessments.

At baseline, EORTC QLQ-C30 scores were available for 114 patients in the ivosidenib group and 53 patients in the placebo group; QLQ-BIL21 scores were available for 108 patients receiving ivosidenib and 52 patients receiving placebo. Over time, the sample sizes for the QOL analyses decreased in both arms, with no QOL assessments available for the placebo cohort after cycle 8 (ie, week 28), and EORTC QLQ-C30 change in scores were available for 17 patients in the ivosidenib cohort at week 52.

From baseline to cycle 27, day 1, patients who continued with ivosidenib therapy maintained their QOL. No changes in scores from baseline that exceeded the 12 to 13 threshold were seen in those receiving ivosidenib on the EORTC QLQ-C30 physical functioning subscale; by contrast, deterioration of clinically meaningful physical functioning was observed after baseline at multiple cycles in the placebo group. In terms of the EORTC QLQ-C30 pain and appetite loss and the QLQ-BIL21 pain and eating subscales, the preservation of QOL among ivosidenib-treated patients was similar to that observed with the EORTC QLQ-C30 physical functioning.

Based on results of the ClarIDHy study, Dr Chamberlain and colleagues concluded that patients with advanced CCA harboring IDH1 mutations who received treatment with ivosidenib maintained their QOL over the duration of treatment.


  1. Zhu AX, Macarulla T, Javle MM, et al. Final overall survival efficacy results of ivosidenib for patients with advanced cholangiocarcinoma with IDH1 mutation: the phase 3 randomized clinical ClarIDHy trial. JAMA Oncol. 2021;7:1669-1677.
  2. Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21:796-807. Erratum in: Lancet Oncol. 2020;21:e462.


Chamberlain CX, Hua Z, Gliser C, et al. Longitudinal trends in health-related quality of life (HRQoL) among patients treated with ivosidenib (IVO) for IDH1-mutated cholangiocarcinoma (CCA) in the ClarIDHy study. Abstract 388.

Related Items

Characterization of Long-Term Survivors in TOPAZ-1
March 2023, Vol 4, No 1
Researchers examined the characteristics, outcomes, and genomic profiles of patients with advanced biliary tract cancer who were treated with durvalumab plus gemcitabine/cisplatin and experienced long-term survival.
MDM2-p53 Antagonist BI 907828 Demonstrated Promising Activity in Patients with Advanced BTC
March 2023, Vol 4, No 1
The novel MDM2-p53 antagonist BI 907828 is being investigated as a first-line treatment in patients with advanced biliary tract cancer.
Treatment and Survival Outcomes with Systemic Therapy for Patients with BTC with IDH1 Mutations: A Retrospective Study
March 2023, Vol 4, No 1
Long-term outcomes were evaluated in patients with IDH1-mutated biliary tract cancer who were treated with systemic therapy.
Phase 2 Study of CTX-009 plus Paclitaxel in Patients with Advanced BTC
March 2023, Vol 4, No 1
CTX-009 plus paclitaxel showed promising efficacy as second- or third-line treatment in patients with advanced biliary tract cancer.
Gunagratinib in Patients with Previously Treated Advanced CCA Harboring FGFR2 Fusions or Rearrangements
March 2023, Vol 4, No 1
Gunagratinib showed promising efficacy as a second-generation FGFR inhibitor and demonstrated potential to treat multiple FGFR pathway abnormalities.
Results from SWOG 1815: GemCis and Nab-Paclitaxel versus GemCis in Advanced BTC
March 2023, Vol 4, No 1
The SWOG 1815 trial found that treatment with gemcitabine/cisplatin and paclitaxel (GAP) did not result in a significant improvement in survival compared with gemcitabine and cisplatin in patients with advanced biliary tract cancer, though GAP may be beneficial in patients with locally advanced disease and GBC.
JCOG1202 Subgroup Analysis: Risk Factors for Early Relapse in Patients Undergoing Curative Resection
March 2023, Vol 4, No 1
A study of patients with resected biliary tract cancer (BTC) found that postoperative CA 19-9 level, tumor differentiation, lymph node metastases, and residual tumor significantly impact early relapse in patients with curatively resected BTC. Similar risk factors were also found in patients receiving adjuvant S-1.
Impact of Gene Expression in 5-FU Metabolic Pathways on Outcomes in Patients Enrolled in JCOG1202
March 2023, Vol 4, No 1
Results from a study evaluating the impact of 5-FU metabolic pathway enzyme expression on outcomes of patients with curatively resected biliary tract cancer showed that relapse-free survival was improved in patients with certain enzymes who received adjuvant S-1.
Atezolizumab with or without Bevacizumab in Combination with GemCis in Advanced BTC: Results from IMbrave 151
March 2023, Vol 4, No 1
Researchers assessed whether VEGF blockade plus chemotherapy with gemcitabine/cisplatin can enhance responses to PD-L1 inhibition by promoting an immune-permissive tumor microenvironment in patients with advanced biliary tract cancer.
Nab-Paclitaxel plus Sintilimab as Second-Line Treatment for Advanced BTC
March 2023, Vol 4, No 1
The safety and efficacy of second-line nab-paclitaxel combined with the anti-PD-1 antibody sintilimab was studied in patients with advanced biliary tract cancer.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: